AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06468735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sarcopenia assessment
Description: Quadriceps muscle thickness measurement at the midpoint between the anterior superior iliac spine and the upper pole of the patella.~Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia
Study NCT06468735 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: visceral fat thickness measurement
Description: Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.
Study NCT06058468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation of right anterior ganglionated plexus
Description: Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration >30% is achieved or if radiofrequency time exceeds 120 seconds.
Study NCT06058468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
Study NCT05244824 — intervention group
Intervention type: OTHER
Intervention: Adaptation into Turkish, Examining The Reliability and Validity for People with RA
Description: Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
Study NCT06415708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Combined With Bendamustine
Description: The treatment is divided into two phases: induction therapy and maintenance therapy Induction therapy: 6 cycles of obinutuzumab (1000 mg, IV) on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6 (28 days/cycle). Bendamustine (90 mg/m2, IV) on Days 1 and 2 of Cycles 1-6.~Maintenance therapy: Patients who achieved at least a partial response after 6 months of induction therapy were eligible to enter the maintenance phase, during which obinutuzumab (1000 mg, IV) was administered every 2 months for 2 years.
Study NCT05338164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cerclage
Description: McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
Study NCT04548713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4% EDTA
Description: Sterile Catheter Lock Solution
Study NCT04548713 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline Lock Solution
Study NCT06295965 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT05832684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZVS101e
Description: ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
Study NCT05725278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiko Platform Behavioural cum mHealth Intervention
Description: Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
Study NCT05725278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care / Business as Usual
Description: Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
Study NCT05338554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
Study NCT05338554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
Study NCT05484271 — intervention group
Intervention type: PROCEDURE
Intervention: Rotator cuff repair
Description: The patients received the arthroscopic rotator cuff repair.
Study NCT04926961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
Study NCT04926961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS)
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
Study NCT06527729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil-loaded liposomes
Description: Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
Study NCT06527729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil gel
Description: Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
Study NCT05571085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
Study NCT05571085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PNF Exercise Program
Description: PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
Study NCT06526845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Conference based rehabilitation
Description: All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching).
Study NCT06526845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based rehabilitation
Description: Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching).
Study NCT06525441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Diet
Description: Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
Study NCT06525441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based Diet
Description: Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
Study NCT04579952 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: The current stimulation will be applied using 35 squares cm wide sponge electrodes
Study NCT04579952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: The current stimulation will be applied using 35 squares cm wide sponge electrodes
Study NCT05744661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Method
Description: Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
Study NCT05744661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemomechanical Method
Description: Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
Study NCT06468683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: After preconditioning with chemotherapy, F01 will be evaluated.
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
Study NCT06418087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
Description: Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit.
Study NCT06344702 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: 70% of nights use CPAP for more than 4 hours
Study NCT05836597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality
Study NCT05836597 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality
Study NCT05509829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy using PICO14.
Study NCT05700357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 20 ml
Description: The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
Study NCT05700357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 25 ml
Description: The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
Study NCT05700357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 30 ml
Description: The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
Study NCT04078139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The MP/RP group
Description: Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT04078139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The RP group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT04102228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1Hz inhibitory rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
Study NCT04102228 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1Hz sham rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
Study NCT04102228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study NCT04102228 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study NCT04952532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
Description: The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
Study NCT06257576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
Study NCT06257576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
Study NCT06242522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone interview
Description: Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
Study NCT06544577 — intervention group
Intervention type: DRUG
Intervention: ELacestrant
Description: 345 mg/day once daily oral dosing
Study NCT05925322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage & Connect Psychotherapy
Description: 9-weeks of weekly psychotherapy sessions focused on social reward exposure
Study NCT05925322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Review and Psychoeducation (SRP)
Description: 9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
Study NCT06516237 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: to determine molecular and epigenetic biomarkers
Description: In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers.
Study NCT05202197 — intervention group
Intervention type: OTHER
Intervention: Smart cupboard
Description: Development of a memory task with the help of a smart cupboard
Study NCT06088680 — intervention group
Intervention type: DEVICE
Intervention: Glycar Pericardial Patch
Description: Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
Study NCT05053087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Continuous Infusion
Description: 0.2% continuous infusion 6mL/hr
Study NCT05053087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Intermittent Bolus
Description: 0.2% intermittent bolus infusion 8mL every 2 hours
Study NCT05053087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline filled catheter
Study NCT05834608 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mechanical ventilator-assisted ventilation
Description: After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.